Testing labs in Madrid

ISO/IEC 17025 accredited by ENAC (No. LE2884) testing laboratory (accreditation status: active). Located at Calle Teresita González Quevedo, 20 – 2ª ES.3, 28020, Madrid, Spain. Official accreditation scope: https://www.enac.es/documents/7020/6db35e80-1fc1-4b8f-a4b2-5d3055810650

Inspection, verification and product-certification body (Entidad Colaboradora de la Administración / Organismo de Control Autorizado) accredited by ENAC, covering urban-planning, environmental and industrial-safety compliance. Operates an acoustic testing laboratory accredited to ISO 17025 (inspection to ISO 17020) and holds ISO 9001 and ISO 14001 certification.

ISO/IEC 17025 accredited by ENAC (No. LE1300) testing laboratory (accreditation status: active). Accredited test areas include: Automotive Materials; Calibration Temperature Pressure; Chemical Spectroscopy; Food Contaminants; Mechanical Tensile Compression Flexural; Water; Water Drinking; Water Environmental; Water Legionella; Water Wastewater. Located at C/ Alfonso XII, nº 62, 28014, Madrid, Spain. Official accreditation scope: https://www.enac.es/documents/7020/bf099aa4-be71-4c6c-91d0-c59bbb0c797b

ISO/IEC 17025 accredited by ENAC (No. LE2470) testing laboratory (accreditation status: active). Located at C/ Princípe de Vergara, 54, 28006, Madrid, Spain. Official accreditation scope: https://www.enac.es/documents/7020/14243e31-d409-4495-ad70-2d0d0422a2b9

ISO/IEC 17025 accredited by ENAC (No. LC10.096) testing laboratory (accreditation status: active). Accredited test areas include: Chemical Elemental Analysis. Located at C/ Agustín de Foxá nº4, 28036, Madrid, Spain. Official accreditation scope: https://www.enac.es/documents/7020/c2e331c4-8227-43df-a7e2-5f7cdc548fd5

Altum Sequencing is a Spanish molecular diagnostics company — a spin-off of the Fundación de Investigación Biomédica del Hospital 12 de Octubre in Madrid — specializing in liquid biopsy-based cancer monitoring platforms. Founded in 2019 by clinicians and researchers from one of Spain's leading oncology centers and headquartered in Leganés, Madrid, the company serves pharmaceutical companies, hospitals, and clinical research organizations (CROs) worldwide. Its core mission addresses the diagnostic gap created by imaging limitations: up to 36% of cancer patients receive incorrect post-treatment assessments, with roughly 8% falsely cleared and 28% subjected to unnecessary toxic therapy. Altum Sequencing's AI-powered platform makes these "invisible patients" visible by detecting residual tumor signals in peripheral blood with extreme molecular sensitivity across 23 cancer types, reporting 99% specificity in B-cell lymphoma and identification of 97% of relapses before clinical manifestation. The company's technology is built on next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) and cell-free DNA (cfDNA) derived from simple peripheral blood draws — the liquid biopsy technique. The patented analytical method creates a personalized tumor molecular fingerprint for each patient at baseline, then tracks that fingerprint longitudinally across serial blood samples. The platform achieves sensitivity of one tumor cell among one million healthy cells, enabling detection of minimal residual disease (MRD) far below the threshold of conventional imaging or standard molecular pathology. This sensitivity delivers clinically actionable signals at every major decision point across the oncology treatment continuum, from post-treatment remission confirmation to early relapse warning years before symptoms emerge. Altum Sequencing offers four integrated assay products designed to map onto each phase of cancer care. DxPanels provides baseline tumor profiling and biomarker identification at diagnosis, establishing the molecular landscape required for personalized longitudinal monitoring. TRACKseq is the flagship MRD assay, enabling clinicians to distinguish responders from non-responders during active treatment, confirm molecular remission, detect early relapse signals, and conduct long-term ctDNA surveillance extending up to five to seven years beyond clinical remission. EVOseq focuses on emerging therapeutic resistance, profiling actionable mutations and resistance mechanisms as tumors evolve under treatment pressure to support timely therapy switching. DUALseq simultaneously measures MRD and pharmacokinetic markers from a single blood draw, developed specifically for patients undergoing allogeneic stem cell transplantation or CAR-T cell therapy, where conventional imaging cannot reliably distinguish graft dynamics from residual malignancy. Clinical validation of the platform spans hematologic malignancies and solid tumors alike. Peer-reviewed publications demonstrate performance in HR-positive early breast cancer (TRACKseq anticipating late relapse before clinical recurrence), acute myeloid leukemia (AML, where the assay achieved 92% sensitivity and 88% specificity and identified high-risk relapse patients months ahead of standard monitoring protocols), acute lymphoblastic leukemia (ALL), bladder cancer, B-cell lymphomas, and non-small cell lung cancer (NSCLC). Genetic profiling of cfDNA has been validated as a complementary diagnostic tool for B-cell lymphoma diagnosis and long-term post-remission surveillance. The breadth of validated indications reflects the platform's tumor-agnostic design — the same NGS infrastructure accommodates any tumor type for which a personalized baseline fingerprint can be constructed. For pharmaceutical companies and CROs, Altum Sequencing provides end-to-end molecular biomarker support across the full drug development lifecycle. Early-phase engagements center on biomarker strategy design and custom assay development tailored to the tumor biology of the investigational compound. During clinical trials, the platform enables real-time pharmacodynamic monitoring, molecular patient stratification, and identification of emerging resistance variants. As programs mature, Altum Sequencing supports companion diagnostic (CDx) development for regulatory submission and post-approval monitoring to fulfill post-market pharmacovigilance requirements. This scalable model is explicitly designed to grow with a therapy program across all phases rather than serving as a single-trial tool, offering pharma sponsors continuity of molecular endpoints from exploratory biomarker studies through to commercial launch. For hospital-based oncology and hematology teams, the platform is engineered for practical integration into standard clinical workflows. Both MRD and pharmacokinetics assays run from a single peripheral blood sample per monitoring cycle, minimizing patient burden and enabling routine serial sampling without additional invasive procedures. Treating physicians receive clear longitudinal outputs at each clinical decision point — disease detected / not detected — facilitating confident management from post-surgical adjuvant therapy selection through long-term remission surveillance. The company works with hospitals and oncology practices globally, providing the kind of real-time tumor dynamic data that Dr. Joaquín Martínez, Chairman and Co-Founder, has described as providing "highly sensitive molecular insights that complement conventional monitoring" and improve long-term patient management. Altum Sequencing's scientific credibility is rooted in its founding at Hospital 12 de Octubre, one of Spain's foremost academic oncology centers, and sustained by an active peer-reviewed publications program. The company has won recognition at South Summit Madrid 2026 in the Health vertical category, Spain's leading startup competition, reflecting both technical innovation and commercial momentum. Its association with the Universidad Carlos III de Madrid (UC3M) further grounds the technology in rigorous academic validation. For pharmaceutical sponsors, academic medical centers, and clinical oncology practices seeking a liquid biopsy partner, Altum Sequencing offers a tumor-informed, personalized ctDNA architecture with demonstrated ultrasensitivity, a multi-product platform covering the full cancer monitoring continuum, and a growing body of peer-reviewed clinical evidence across hematologic and solid tumor indications — all accessible via a single peripheral blood sample and a unified NGS analysis pipeline.